Mepolizumab
Mepolizumab (pronounced meh-poh-LIZ-uh-mab) is a monoclonal antibody medication used in the treatment of severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA).
Etymology
The name "Mepolizumab" is derived from the International Nonproprietary Names (INN), with "mab" at the end indicating it is a monoclonal antibody.
Usage
Mepolizumab is used to treat severe eosinophilic asthma that is not controlled with other asthma medicines. It is also used to treat eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease.
Mechanism of Action
Mepolizumab works by reducing the number of eosinophils, a type of white blood cell that contributes to the symptoms of asthma and EGPA. It does this by blocking the action of a certain substance in the body that controls the production of eosinophils.
Side Effects
Common side effects of Mepolizumab include headache, injection site reactions, back pain, and fatigue. Serious side effects may include allergic reactions, herpes zoster infection, and possibly an increased risk of heart attack.
Related Terms
External links
- Medical encyclopedia article on Mepolizumab
- Wikipedia's article - Mepolizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski